Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.48 |
| ▸ | EYA2 | O00167 | 1/20 | 0.48 |
| ▸ | APP | P05067 | 1/20 | 0.48 |
| ▸ | ACE | P12821 | 1/20 | 0.48 |
| ▸ | BLM | P54132 | 2/20 | 0.46 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.46 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | DRD1 | P21728 | 1/20 | 0.46 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.46 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.46 |
| ▸ | DRD3 | P35462 | 1/20 | 0.46 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.46 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3129632 | 1.00 | TDP1 (0.48) | TDP1EYA2APPACEBLM | |
| SCHEMBL16631799 | 1.00 | TDP1 (0.48) | TDP1EYA2APPACEBLM | |
| SCHEMBL16631806 | 1.00 | TDP1 (0.48) | TDP1EYA2APPACEBLM | |
| SCHEMBL16631804 | 1.00 | TDP1 (0.48) | TDP1EYA2APPACEBLM | |
| SCHEMBL9119071 | 0.95 | TDP1 (0.43) | TDP1EYA2APPACEBLM | |
| SCHEMBL9119114 | 0.93 | TDP1 (0.42) | TDP1EYA2APPACEBLM | |
| SCHEMBL18021177 | 0.93 | TDP1 (0.42) | TDP1EYA2APPACEBLM | |
| SCHEMBL408772 | 0.93 | TDP1 (0.42) | TDP1EYA2APPACEBLM | |
| SCHEMBL13014046 | 0.93 | TDP1 (0.42) | TDP1EYA2APPACEBLM | |
| SCHEMBL16631807 | 0.92 | TDP1 (0.56) | TDP1EYA2APPACEBLM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 258 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260108637-A1 | USES OF PSMA-TARGETING AND TSPO-TARGETING COMPOUNDS FOR EVALUATION OF INJURIES IN THE PERIPHERAL NERVOUS SYSTEM | UNIV JOHNS HOPKINS (US) | 2026-04-23 | — | — | US | claimed |
| EP-4719494-A2 | USES OF PSMA-TARGETING AND TSPO-TARGETING COMPOUNDS FOR EVALUATION OF INJURIES IN THE PERIPHERAL NERVOUS SYSTEM | The Johns Hopkins University (US) | 2026-04-08 | — | — | EP | claimed |
| US-20250360218-A1 | MITOCHONDRIA-TARGETING CANCER THERAPEUTIC COMPOSITION | SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION (KR) | 2025-11-27 | — | — | US | claimed |
| US-20250340701-A1 | DENDRIMER-DELIVERED ALPHA-PARTICLE RADIOTHERAPY FOR TREATMENT OF GLIOBLASTOMA AND OTHER CANCERS IN THE BRAIN | UNIV JOHNS HOPKINS (US) | 2025-11-06 | — | — | US | claimed |
| EP-4615521-A1 | KETO-AMIDE-BASED FIBROBLAST ACTIVATION PROTEIN-TARGETED LIGAND LINKED TO AN IMAGING OR THERAPEUTIC AGENT, COMPOSITIONS AND METHODS OF USE | Purdue Research Foundation (US) | 2025-09-17 | — | — | EP | claimed |
| EP-4590346-A1 | FIBROBLAST ACTIVATION PROTEIN (FAP) INHIBITORS, FAP CONJUGATES, AND DIAGNOSTIC AND THERAPEUTIC USES THEREOF | Nuclidium AG (CH) | 2025-07-30 | — | — | EP | claimed |
| EP-4590345-A2 | HIGH-PURITY COPPER RADIOPHARMACEUTICAL COMPOSITIONS AND DIAGNOSTIC AND THERAPEUTIC USES THEREOF | Nuclidium AG (CH) | 2025-07-30 | — | — | EP | claimed |
| WO-2025151464-A1 | ALPHA-PARTICLE RADIONUCLIDE-ANTIBODY CONJUGATES FOR TREATMENT OF SOLID TUMORS | THE JOHNS HOPKINS UNIVERSITY (US) | 2025-07-17 | — | — | WO | claimed |
| US-20250135047-A1 | IMPROVED ALUMINUM FLUORIDE RADIOSYNTHESIS OF [18F]DK222 | THE JOHNS HOPKINS UNIVERSITY | 2025-05-01 | — | — | US | claimed |
| WO-2025049985-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER USING AN INHIBITOR OF PRM T5 | PURDUE RESEARCH FOUNDATION (US) | 2025-03-06 | — | — | WO | claimed |
| WO-2022241279-A2 | FOLATE RECEPTOR-TARGETED CONJUGATES WITH BRUSH BORDER MEMBRANE ENZYME-CLEAVABLE LINKERS AND METHODS OF USE IN IMAGING AND TREATING CANCER | PURDUE RESEARCH FOUNDATION (US) | 2022-11-17 | — | — | WO | claimed |
| EP-4081263-A1 | RADIOLABELED PEPTIDES FOR NON-INVASIVE DIAGNOSIS AND TREATMENT OF CXCR4 EXPRESSING TUMORS | Istituto Nazionale Tumori IRCCS - Fondazione G. Pascale (IT) | 2022-11-02 | — | — | EP | claimed |
| WO-2022212958-A1 | HETEROBIVALENT AND HOMOBIVALENT AGENTS TARGETING FIBROBLAST ACTIVATION PROTEIN ALPHA AND/OR PROSTATE-SPECIFIC MEMBRANE ANTIGEN | THE JOHNS HOPKINS UNIVERSITY (US) | 2022-10-06 | — | — | WO | claimed |
| WO-2022174809-A1 | ANTI-CLDN18.2 ANTIBODY CONJUGATES | Suzhou Transcenta Therapeutics Co., Ltd. (CN) | 2022-08-25 | — | — | WO | claimed |
| WO-2022133537-A1 | LIGANDS AND THEIR USE | THE UNIVERSITY OF SYDNEY (AU) | 2022-06-30 | — | — | WO | claimed |
| US-20220118116-A1 | ADHESIVE/ADSORPTION SWITCH ON NANOPARTICLES TO INCREASE TUMOR UPTAKE AND DELAY TUMOR CLEARANCE | THE JOHNS HOPKINS UNIVERSTY | 2022-04-21 | — | — | US | claimed |
| WO-2022032100-A2 | IMAGING AND TARGETING PROGRAMMED DEATH LIGAND-1 (PD-LI) EXPRESSION | THE JOHNS HOPKINS UNIVERSITY (US) | 2022-02-10 | — | — | WO | claimed |
| WO-2021130329-A1 | RADIOLABELED PEPTIDES FOR NON-INVASIVE DIAGNOSIS AND TREATMENT OF CXCR4 EXPRESSING TUMORS | ISTITUTO NAZIONALE TUMORI IRCCS - FONDAZIONE G. PASCALE (IT) | 2021-07-01 | — | — | WO | claimed |
| US-8697034-B2 | Hyperpolarized 89-yttrium and methods relating thereto | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2014-04-15 | — | — | US | claimed |
| US-20100092396-A1 | HYPERPOLARIZED 89-YTTRIUM AND METHODS RELATING THERETO | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2010-04-15 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250360218-A1 | MITOCHONDRIA-TARGETING CANCER THERAPEUTIC COMPOSITION | TSPO, TFAM, MCU | TDP1 2579/4885EYA2 3608/4885APP 1566/4885 |
| US-20220118116-A1 | ADHESIVE/ADSORPTION SWITCH ON NANOPARTICLES TO INCREASE TUMOR UPTAKE AND DELAY TUMOR CLEARANCE | EPCAM, ICAM1, CD44 | TDP1 4681/4885EYA2 2470/4885APP 1318/4885 |
| US-20250340701-A1 | DENDRIMER-DELIVERED ALPHA-PARTICLE RADIOTHERAPY FOR TREATMENT OF GLIOBLASTOMA AND OTHER CANCERS IN THE BRAIN | TUBA3E, TUBB2A, ADCYAP1R1 | TDP1 1523/4885EYA2 3829/4885APP 2068/4885 |
| US-20260108637-A1 | USES OF PSMA-TARGETING AND TSPO-TARGETING COMPOUNDS FOR EVALUATION OF INJURIES IN THE PERIPHERAL NERVOUS SYSTEM | MUSK, TNNC1, TNNI3 | TDP1 745/4885EYA2 3788/4885APP 1321/4885 |
| US-20100092396-A1 | HYPERPOLARIZED 89-YTTRIUM AND METHODS RELATING THERETO | TSPO, IPO11, SLC30A5 | TDP1 623/4885EYA2 3943/4885APP 3810/4885 |
| US-20250135047-A1 | IMPROVED ALUMINUM FLUORIDE RADIOSYNTHESIS OF [18F]DK222 | PDCD1LG2, CD274, PDCD1 | TDP1 2019/4885EYA2 3317/4885APP 1115/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.